Drug DeliveryFebruary 2026
Crossing the Uncrossable: How VHH Engineering Solves the BBB Delivery Challenge
Recent publications on receptor-mediated transcytosis and single-domain antibody formats confirm that VHH nanobodies below 15 kDa achieve meaningful CNS penetration — a pharmacokinetic advantage inaccessible to conventional IgG antibodies.
JFInnova Perspective
JFIN-0001 (12.6 kDa) sits squarely in the optimal BBB-penetrant window. Our interactive BBB Simulator models the PK advantage in real time, including albumin-fusion half-life extension strategies.
References
1
NANOBODIES: A Review of Generation, Diagnostics and Therapeutics
International Journal of Molecular Sciences · 2023
VHH blood-brain barrier penetration